Novo Nordisk's Coramitug cut NT-proBNP levels and was well tolerated in a Phase 2 ATTR-CM trial, paving the way for its Phase 3 CLEOPATTRA study.

Please provide your email address to receive an email when new articles are posted on . The PARALLAX trial of sacubitril/valsartan for HF with preserved ejection fraction met one of its two co-primary ...

Still, they also had better diastolic function, superior right ventricular function, and lower left atrial volume and mitral/tricuspid regurgitation vs the persons with high NT-proBNP levels, despite ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The same ...

Using an implantable loop recorder (ILR) to screen older individuals for atrial fibrillation (AF) may be more beneficial when NT-proBNP levels are high, according to a post hoc analysis of the LOOP ...

In people with no history of CV disease, N-terminal pro-brain natriuretic peptide (NT-proBNP) levels can predict a higher risk of developing CV disease across various blood pressure and pulse pressure ...

In this new subanalysis of data from the Atherosclerosis Risk in the Communities study, investigators assessed the risk of incident heart failure (HF) or death by race and sex, as influenced by ...

San Francisco, CA - Patients with stable coronary disease could potentially avoid echocardiographic or nuclear studies of ventricular function if their serum natriuretic peptide levels are low, ...

In an update on nex-z's phase I study, the CRISPR-Cas9 gene therapy stayed the course out to 3 years in an initial 36-person ...

Background and aim: Cardiac troponin I (cTnI) and natriuretic peptide NT-proBNP are useful biomarkers in the evaluation of the sick heart. We aimed to detect a potential early postoperative myocardial ...

Cardiac performance in patients with HF can be determined with measurement of the time for peak oxygen uptake to decrease by more than 12.5%.